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Abstract: Cancer is the second leading cause of death in the world and one of the major public
health problems. Despite the great advances in cancer therapy, the incidence and mortality rates of
cancer remain high. Therefore, the quest for more efficient and less toxic cancer treatment strategies
is still at the forefront of current research. Curcumin, the active ingredient of the Curcuma longa
plant, has received great attention over the past two decades as an antioxidant, anti-inflammatory,
and anticancer agent. In this review, a summary of the medicinal chemistry and pharmacology
of curcumin and its derivatives in regard to anticancer activity, their main mechanisms of action,
and cellular targets has been provided based on the literature data from the experimental and clinical
evaluation of curcumin in cancer cell lines, animal models, and human subjects. In addition, the recent
advances in the drug delivery systems for curcumin delivery to cancer cells have been highlighted.
Keywords: curcumin; anticancer; structure activity relationship; cellular pathway; mechanism of
action; delivery system
1. Introduction
Cancer is the second most life-threatening disease and one of the main public health problems
worldwide. In 2018, there were around 1.73 million new cases of cancer and more than 609,000 deaths
in the United States alone [1]. Despite the tangible advances in cancer therapy, the reported incidence
of the disease and the mortality have not declined in the past 30 years [2]. Understanding the molecular
alterations that contribute to cancer development and progression is a key factor in cancer prevention
and treatment. There are several common strategies for targeting specific cancer cells to inhibit tumor
development, progression, and metastasis without causing severe side effects [3]. In addition to the
chemically synthesized anticancer agents, several anticancer compounds with different modes of
action have been extracted from plant sources, such as Taxus brevifolia, Catharanthus roseus, Betula alba,
Cephalotaxus species, Erythroxylum previllei, Curcuma longa, andmany others [4]. Among them, curcumin
is the most important component of the rhizomes of Curcuma longa L. (turmeric) [5] and was extracted
from turmeric plant in a pure crystalline form for the first time in 1870 [6]. Curcumin and its derivatives
have received immense attention in the past two decades due to their biofunctional properties such as
anti-tumor, antioxidant, and anti-inflammatory activities [7]. These properties are attributed to the
key elements in the curcumin structure [8]. Therefore, a great deal of scientific work has shed light on
the structure activity relationship (SAR) of curcumin in an attempt to improve its physiochemical and
biological properties. Due to the importance of cancer as a leading cause of death and the ongoing quest
for more efficient and less toxic anticancer agents, this review has mainly focused on the anticancer
activity of curcumin. The applications of curcumin in other diseases are beyond the scope of this
review and have been reviewed elsewhere [4,9].
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The main mechanisms of action by which curcumin exhibits its unique anticancer activity
include inducing apoptosis and inhibiting proliferation and invasion of tumors by suppressing a
variety of cellular signaling pathways [10]. Several studies reported curcumin’s antitumor activity
on breast cancer, lung cancer, head and neck squamous cell carcinoma, prostate cancer, and brain
tumors [11], showing its capability to target multiple cancer cell lines. In spite of all the above
mentioned advantages, curcumin’s applications are limited due to its low water solubility which
results in poor oral bioavailability and also low chemical stability [7]. Another obstacle is the low
cellular uptake of curcumin. Due to its hydrophobicity, the curcumin molecule tends to penetrate into
the cell membrane and bind to the fatty acyl chains of membrane lipids through hydrogen binding
and hydrophobic interactions, resulting in low availability of curcumin inside the cytoplasm [12,13].
To overcome these obstacles and improve the overall anticancer activity of curcumin, several structural
modifications have been suggested to enhance selective toxicity towards specific cancer cells [14],
increase bioavailability, or enhance stability [4,15]. Another approach is to use different delivery
systems to improve curcumin’s physiochemical properties and anticancer activity. This review focuses
on the recent literature on the SAR of curcumin and its analogues and their anticancer activity in
different cancer cell lines, animal models, and human clinical trials as well as different types of
curcumin delivery systems that have been used for cancer therapy.
2. Structure Activity Relationship of Curcumin and Its Derivatives
Chemical structure modification does not only affect the receptor binding and pharmacological
activity of a drug molecule but also alters its pharmacokinetics and physiochemical properties [4].
Determining the essential pharmacophores within a drug molecule requires a thorough study
of its natural and synthetic analogues [11]. The chemical structure of curcumin is depicted in
Figure 1A. As can be observed, it consists of two phenyl rings substituted with hydroxyl and
methoxyl groups and connected via a seven carbon keto-enol linker (C7). While curcumin is naturally
derived, its derivatives are generally produced by a chemical reaction between aryl-aldehydes and
acetylacetone. This assembly method can yield multiple chemical analogues, such as compounds with
alkyl substituents on the middle carbon of the linker (C7 moiety) [16,17]. A SAR study of curcumin
derivatives demonstrates that the presence of a coplanar hydrogen donor group and a β-diketone
moiety is essential for the antiandrogenic activity for the treatment of prostate cancer [17]. In addition,
scanning 50 curcumin analogues showed that shortening the linker from seven carbon atoms (C7)
to five carbon atoms (C5) improves the antiandrogenic activity [18]. As a result of introducing a
methyl group at both C2 and C6 positions, a new curcumin derivative has been produced (Figure 1B).
This derivative exhibited a steric hindrance effect toward metabolizing enzymes, such as alcohol
dehydrogenase [14], and demonstrated significantly higher activity than curcumin in inhibiting
endothelial cell proliferation and invasion both in vitro and in vivo [14]. Dimethylcurcumin or
ASC-J9 (5-hydroxy-1, 7-bis (3, 4-dimethoxyphenyl)-1, 4, 6-heptatrien-3-one) is a newly developed
curcumin analogue which enhances androgen receptor degradation and has been used for treatment
of prostate cancer [19–21]. Moreover, it has also shown a significant antiproliferative effect against
estrogen-dependent breast cancer cells [22]. Although methylation has enhanced the targetability and
activity of the molecule, it has also increased its hydrophobicity massively compared to curcumin,
which has limited its administrable dose in cancer therapy [23].
Furthermore, studies on the kinetic stability of synthetic curcumin derivatives have pointed out
that glycosylation of the pharmacophore aromatic ring improves the compound’s water solubility,
which enhances its kinetic stability and leads to a better overall therapeutic response [24]. During phase
I and phase II metabolism, the main routes of converting curcumin into a higher excretable form are
oxidation, reduction, and conjugation (glucuronidation and sulfurylation). The conjugation reactions
occur on the hydroxyl groups (4-OH) attached to the phenyl rings of curcumin. Thus, curcumin’s
kinetic stability can be enhanced by masking the 4-OH groups [25]. Another study has revealed a
correlation between the hydrophobic property of the benzyl rings and androgen receptor affinity [26].
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The benzyl rings are also crucial for inhibiting tumor growth, and adding hydrophobic substituents,
such as CH3 groups, on them (R1, R2, R3, R4 in Figure 1B) have been linked to the increased antitumor
activity of curcumin derivatives [26,27]. O-methoxy substitution was found to be more effective in
suppressing nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), but this modification
has also affected the lipophilicity of curcumin [28]. A summary of the potential sites of modification
on the curcumin molecule is illustrated in Figure 1B.

ˊ ˊ
Figure 1. (A) Chemical structure of curcumin. (B) The main pharmacophores and potential
substitution positions.
Some of the modified curcuminoids exhibit enhanced anticancer and anti-inflammatory activities
compared to curcumin due to the low level of hydrogenation, high level of methoxylation,
and unsaturation of the diketone moiety [29]. Ortho-methoxy substitution of the essential radical of
curcuminoid alters the heptadiene moiety and the hydrogenation level [28]. A comparative study on
curcumin and its derivatives revealed stronger antioxidant activity for several hydrogenated curcumin
derivatives compared to the original curcumin compound [30]. For example, tetrahydrocurcumin
(THC) exhibited higher antioxidant activity than dihydrocurcumin (DHC) and unmodified
curcumin [31,32] (Table 1). Unlike curcumin, THC, which is a non-electrophilic derivative, failed to
suppress the signal transducer and activator of transcription 3 (STAT3) signaling pathway and induce
apoptosis. This suggests that the electrophilic nature of curcumin is essential for inhibiting the STAT3
signaling pathway during anticancer therapy [33]. Metallo-curcumin-conjugated DNA complexes
have been constructed using Cu2+/Ni2+/Zn2+ metal ions to improve curcumin solubility and enhance
DNA-binding ability [34]. These complexes also showed a better antibacterial activity and significant
toxicity to several prostate cancer cell lines [34] (Table 1).
In addition to anticancer and anti-inflammatory properties, curcuminoids exert antioxidant
activity mainly through the chelating effect of the diketone moiety. The presence of metals such as
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Cu2+, Fe2+, and Pb2+ boost the chelating power of curcumin derivatives [35]. The unsaturated diketone
group in curcumin root is a Michael reaction acceptor, part of phase II enzyme inducers [4], which
can be responsible for NF-κB suppression in cancer cells. However, an investigation on 72 different
curcumin derivatives did not find a direct correlation between the inhibition of tumor growth through
NF-κB and antioxidant activity [36]. O-methoxy substitution resulted in increased antioxidant activity
of curcumin only when the methoxy group was not linked to the proton acceptor β-diketone moiety
through conjugation [4]. The equilibrium between the keto and enol forms of curcumin relies on
environmental factors such as pH. The keto form is dominant at acidic or neutral pH, while the enol
form is more common in basic pH [37]. This unique property has been exploited in the discovery of
new curcumin nanoassemblies with a buffering capacity that exhibit the “proton sponge effect” in
endosomes and lysosomes [7].
Table 1. Changes to the pharmacological activity of curcumin derivatives compared to curcumin.
Curcumin Derivative Chemical Modification Activities References
Dimethyl curcumin
(ASC-J9)
Methyl groups substitution on
R2 and R4
Enhanced activity toward prostate
and breast cancer
[20–22,38]
Vanadium, gallium, and
indium complexes
Metal complexation by the
β-diketones
Enhanced cytotoxic activity [39]
Tetrahydrocurcumin
(THC)
Hydrogenated diketone
moiety
Enhanced antioxidant activity but
loss of DNA binding and STAT3 a
inhibition properties
[31,33]
Modified aromatic rings
curcumin compounds
Introduction of cyclohexane
bridge
Improved mitochondrial membrane
permeability during
lymphoma therapy
[40]
Metallo-curcumin
(Cu2+/Ni2+/Zn2+)
Metal complexation by the
β-diketones
Enhanced water-solubility and
improved DNA binding
[34]
Glycosylated curcumin
derivative
Glycol groups substitution on
the aromatic rings
Higher potency, aqueous solubility,
and chelating properties
[41]
Cu2+ conjugate of
synthetic curcumin
analogues
Conjugation reaction on the
keto-enol moiety
Stronger inhibition of TNF
b-induced NF-κB c activation in
leukemic KBM-5 cells
[42]
Cyclic curcumin
derivatives
Boron trioxide-mediated aldol
condensation
Enhanced cytostatic, antitumor, and
antioxidant activity
[43]
Curcumin carbocyclic
analogues
Introducing carboxyl group at
the diketone moiety
Enhanced antioxidant activity and
stronger inhibition of HIV d
1 protease
[44]
Hydrazinocurcumin
Replacing the diketone moiety
with hydrazine derivative
Higher efficacy in inhibition of
colon cancer progression via
antagonism of Ca2+/CaM e function
[45,46]
Semicarbazone
Introducing NNHCONH2 at
the keto-enol moiety
Enhanced antioxidant, antiradical,
and antiproliferative activity
[47]
a STAT3: signal transducer and activator of transcription 3; b TNF: Tumor necrosis factor; c NF-κB: nuclear
factor κ-light-chain-enhancer of activated B cells; d HIV: Human immunodeficiency virus; e Ca2+/CaM:
calcium/calmodulin.
Although curcumin has low water solubility and poor bioavailability, it enjoys a strong
pharmacological effect in clinical applications [48]. A novel study attempted to explain this unique
property of curcumin by testing the pharmacological effect of curcumin’s metabolites resulting from
physiological degradation. The parallel docking calculations of curcumin degradation products were
found to be similar to those of curcumin because they share with the original compound the same
binding pockets required for inhibiting several enzymes [48].
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3. Different Types of Curcumin Delivery Systems Used in Cancer Therapy
Various delivery systems for curcumin have been formulated using different nanotechnologies in
order to improve curcumin properties and targetability. For the rational design of the nanoformulations,
several factors should be considered in order to enhance the efficacy and improve the cellular targeting
of the anticancer agents. These factors include the nanoparticle size and shape, surface properties,
and nanoparticle targeting ligands [49], as illustrated in Figure 2. A summary of the most commonly
used curcumin delivery systems is introduced in this section.

Figure 2. Examples of current nanoparticle design strategies used to improve targeting.
3.1. Polymeric Nanoparticles
Various polymers have been utilized to prepare nanoformulations for curcumin drug delivery to
improve its biological activity [50]. The biocompatible and biodegradable polymers are preferred in the
drug delivery systems due to lower risk of toxicity [51]. Therefore, biodegradable synthetic polymers
such as PLGA (poly (D, L-lactic-co-glycolic acid) and natural polymers such as silk fibroin and chitosan
have become widely used in drug delivery [52–54]. PLGA-curcumin nanoformulation was found to be
as effective as curcumin at 15-fold lower concentration in inhibitingmRNAs for inflammatory cytokines
(CXCR3 and CXCL10) and increasing anti-inflammatory cytokine interleukin-10 (IL-10) in the brain [55].
In vivo study in rats showed that the bioavailability of curcumin-PLGA nanospheres was increased
nine-fold in comparison to unprocessed curcumin administrated with alkaloid compound piperine.
However, curcumin/piperine coadministration enhanced curcumin activity by inhibiting hepatic and
intestinal deactivation [56]. Another study compared the anticancer activity of curcumin-loaded PLGA
nanoparticles (CUR-NPs) and curcumin-loaded PLGA nanoparticles conjugated to anti-P-glycoprotein
(P-gp) (CUR-NPs-APgp). The latter formulation showed significantly more specific binding to cervical
cancer cells KB-3-1 but lower entrapment efficiency compared to CUR-NPs [57]. Spherical PLGA
nanospheres were also developed to encapsulate dimethyl curcumin (ASC-J9) and tested in breast
Int. J. Mol. Sci. 2019, 20, 1033 6 of 26
cancer cells. The PLGA nanospheres were capable of releasing ASC-J9 intracellularly, leading to growth
inhibition of estrogen-dependent MCF-7 cancer cells [22].
3.2. Liposomes
Nanoscale liposomes are emerging as one of the most useful drug delivery systems for
anticancer agents. Recent advances in liposome formulations have resulted in improved treatment for
drug-resistant tumors and reduced toxicity [58]. A liposome consists of a phospholipid bilayer
shell and an aqueous core which makes it an ideal carrier for encapsulating both hydrophobic
and hydrophilic compounds. Several liposome preparations have been utilized to encapsulate
curcumin (Table 2). The liposomal lipid bilayer (such as egg yolk phosphatidyl choline (EYPC),
dihexyl phosphate (DHP) and cholesterol) solubilizes curcumin. This preparation was found to
stabilize loaded curcumin proportionally to its content [59]. Another work on liposomes tested
coating liposomes with lipid–polymer conjugate N-dodecyl chitosan-N-[(2-hydroxy-3-trimethylamine)
propyl] (HPTMA) chloride. Positively charged nanoliposomes for curcumin delivery have also
been developed by incorporating polyethylene glycol (PEG) and cationic polyethyleneimine (PEI)
into the formulation. Despite low encapsulation efficiency (45%), this formulation has demonstrated
twenty-fold higher cytotoxic activity than unprocessed curcumin in various cell lines, including human
HepG2 hepatocellular carcinoma, A549 lung carcinoma, HT29 colorectal carcinoma, and cervical
carcinoma [60]. In liposomal gene delivery, an interesting work conducted by Fujita et al. [61]
utilized curcumin to control siRNA release. By incorporating curcumin into the liposomal formula,
siRNA release showed a bell-shaped pattern due to the dose-dependent increase in liposomal
permeability induced by curcumin. Curcumin-loaded liposomes were also used to inhibit the
production of IL-6 in macrophages. The liposomes were prepared by mixing curcumin solution
with human serum albumin (HSA) solution and subsequently adding this mixture to a lipid
mixture containing 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1, 2-dipalmitoyl-sn-glycero-
3-phospho-L-serine sodium salt (DPPS) and cholesterol. The designed system induced significant IL-6
suppression and reduction in the total number of macrophages [62] (Figure 3).
Table 2. Examples of recent curcumin delivery systems.
Nanoformulation Particle Size Application Outcome Reference
Curcumin-loaded liposomal
PMSA a antibodies
100–150 nm
Human prostate cancer
(LNCa, C4-2B)
Enhanced antiproliferative
efficacy and targeting
[63]
Curcumin-loaded magnetic
silk nanoparticles
100–350 nm
Human breast cancer
(MDA-MB-231) cells
Enhanced cellular uptake
and growth inhibition
[54]
Curcumin/MPEG b-PCL c
micelles
27 ± 1.3 nm
Colon carcinoma (C-26)
cells
Enhanced cancer growth
inhibition
[64]
Curcumin nanoemulsion <200 nm
Human ovarian
adenocarcinoma cells
(SKV3)
Increased cytotoxicity [65]
Curcumin loaded liposomes
coated with N-dodecyl
chitosan-HPTMA d chloride
73 nm
Murine fibroblasts
(NIH3T3) and murine
melanoma (B16F10) cells
Specific toxicity in murine
melanoma (but not in
fibroblasts)
[66]
Curcumin-PLGA e
nanoparticles
248 ± 1.6 nm
Erythroleukemia type
562 cells
Improved clinical
management of leukemia
[65]
Curcumin loaded lipo-PEG
f-PEI g complexes
269 nm
Melanoma (B16F10) and
colon carcinoma (CT-26)
cells
Increased cytotoxicity [67]
Curcumin–chitosan
nanoparticles
100–250 nm Melanomas Enhanced antitumor effect [68]
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Table 2. Cont.
Nanoformulation Particle Size Application Outcome Reference
ApoE h
peptide-functionalized
curcumin-loaded liposomes
132 nm RBE4 cell monolayer
Increased accumulation in
brain capillary
endothelium
[69]
Curcumin-crosslinked
polymeric Nanogels
10–200 nm
Breast and pancreatic
cancers
Higher stability and
enhanced antitumor effect
[70]
Curcumin-loaded chitin
nanogels
70–80 nm
Human skin melanoma
(A385) and human
dermal fibroblasts (HDF)
Specific toxicity in skin
melanoma (lower toxicity
in HDF)
[70]
Curcumin-loaded lipid-core
nanocapsules
196 ± 1.4 nm
Rat C6 and U251MG
glioma cell lines
Decreased tumor size and
prolonged survival
[71]
Liposome-encapsulated
curcumin
Not reported
Head and neck
squamous cell carcinoma
(HNSCC) cell lines
(CAL27 and UM-SCC1)
Cancer growth
suppression both in vitro
and in vivo
[72]
a PMSA: Prostate membrane specific antigen; b MPEG: Monomethoxy poly ethylene glycol; c PCL:
Poly(ε-caprolactone); d HPTMA: N-[(2-hydroxy-3-trimethylamine) propyl; e PLGA: Polylactic-co-glycolic acid;
f PEG: Poly ethylene glycol; g PEI: Polyethyleneimine; h ApoE: Apolipoprotein E.

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Figure 3. (A) Schematic representation of curcumin-loaded liposomes inducing a reduction in the
number of macrophages [62]. HSA: human serum albumin; DPPC: 1, 2-dipalmitoyl-sn-glycero-3-
phosphocholine; DPPS: 1, 2-dipalmitoyl-sn-glycero-3-phospho-L-serine. (B) curcumin-loaded
liposomes inhibit production of IL-6; white, grey, and black columns represent control, unloaded
liposomes, and curcumin-loaded liposomes respectively. Reprinted from Amano et al. [62].
3.3. Nanogels
Although hydrogels and nanogels have gained considerable attention in the past decade as
a promising drug delivery system, only a few studies have investigated the curcumin-nanogel
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delivery in cancer therapy. There are several polymeric hydrogel nanoparticle systems that have
been prepared recently using synthetic or natural polymers. Among the natural polymers, chitosan,
chitin, and alginate are the most studied for the preparation of nanogels in drug delivery [73]. On the
other hand, the most commonly used synthetic polymers are polyvinyl alcohol (PVA), polyethylene
oxide (PEO), polyethyleneimine (PEI), polyvinyl pyrrolidone (PVP), and poly-N-isopropylacrylamide
(PNIAA) [74]. One of the main advantages of natural hydrogels over synthetic ones when used in
drug delivery is biodegradability and biocompatibility [70,74]. Additionally, nanogels possess unique
features, including large surface area for drug entrapment and a porous structure for drug loading
and release [70,75]. A curcumin-loaded chitin nanogel has been used as a transdermal system for
the treatment of skin cancer [70] (Table 2) and has shown more specific toxicity towards human skin
melanoma (A375) in comparison to human dermal fibroblast (HDF) cells without compromising the
antitumor activity of curcumin [70]. In another study, a hybrid nanogel system consisting of alginate,
chitosan, and pluronic polymers was prepared via the polycationic crosslinking method and tested
on a HeLa cell line [76]. This delivery system demonstrated very high entrapment efficiency, and a
significant difference in cell proliferation was observed between the cells treated with unprocessed
curcumin and the cells treated with curcumin-loaded hybrid nanogel [76].
3.4. Peptide and Protein Formulations
As discussed earlier, hydrogels and polymeric materials have shown promising results in
curcumin drug delivery. However, a few limitations have arisen in processing clinical applications,
including toxicity of unreacted monomers, post-crosslinking shrinkage or fragility of the polymer
gels, and rapid discharge of a large amount of the loaded drug during the initial burst release
in drug carrier [77]. In an attempt to address these limitations, self-assembling peptide systems
have been developed. Peptides provide several benefits when introduced to drug delivery systems,
such as biocompatibility, desirable hydrophilicity, and mild processing conditions [78]. A recent study
investigated the physical properties and therapeutic efficacy of a curcumin-loaded, self-assembling
(MAX8) peptide (β-hairpin) hydrogel system. This newly developed system has combined multiple
advantages such as enhanced delivery, curcumin stabilization, and controlled drug release by
changing the MAX8 peptide concentration [79]. In another example, an amphiphilic polypeptide
(β-casein) was able to self-assemble into micelles. Encapsulation of curcumin within the hydrophobic
core of the β-casein micelles increased its aqueous solubility by 2500 times [80]. Human serum
albumin (HSA) is one of the most commonly used proteins in nanoparticle preparation due to its
excellent biocompatibility [81]. Curcumin-loaded HSA nanoparticles have been produced through the
homogenization of aqueous HSA solution (to crosslink the HSA molecules) and curcumin dissolved in
chloroform. This formulation improved the curcumin solubility by 300 times but only achieved
7.2% curcumin loading efficiency, which was likely due to entrapment of curcumin within the
albumin hydrophobic cavity through hydrophobic interactions [82]. Recently, silk fibroin (SF) protein
has attracted tremendous attention due to its excellent biocompatibility and multiple biomedical
applications [83]. Since its approval by the FDA, several studies have investigated its potential
applications in drug delivery [84]. Magnetic silk nanoparticles (MSPs) were used to deliver curcumin
to MDA-MB-231 breast cancer cells. As illustrated in Figure 4, these particles were fabricated using
the salting-out method to convert silk from its α-helix form to the β-sheet (the insoluble) form,
thus providing a hydrophobic surface for curcumin loading. The designed nanoformulation managed
to achieve a small particle size (100–350 nm), cell internalization, and the possibility for additional
targeting using an external magnetic field on the target tissue [54].
Int. J. Mol. Sci. 2019, 20, 1033 9 of 26

 
 
 
΅ Ά ·
Figure 4. (A) Fabrication of magnetic silk particles (MSP) for curcumin delivery. (B) Atomic force
microscopy (AFM) images of MSP before and after curcumin loading. (C) Representative microscopic
images of MDA-MB-231 cells incubated with free curcumin and curcumin-loaded MSP showing a
significant improvement of curcumin cellular uptake. Reprinted from Song et al. [54], copyright ©
2017 ACS.
3.5. Cyclodextrin Complexes
Cyclodextrins are cyclic oligosaccharides which consist of a hydrophilic outer layer and a
lipophilic core. In drug delivery, these complexes provide several beneficial properties, including
enhanced solubility, increased bioavailability, and improved stability of the loaded drug. There are
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different types of cyclodextrins, such as natural (α, β, and γ), chemically modified, and polymerized
cyclodextrins, that vary in water solubility and molecular weight [85]. There are also different
cyclodextrin complexes, including inclusion complexes and self-assembled cyclodextrins (Figure 5A).
Few studies have used cyclodextrins as carriers in curcumin delivery to enhance bioavailability,
minimize degradation, and reduce nonselective toxicity [86]. A β-cyclodextrin–curcumin
self-assembling preparation has shown higher uptake of curcumin by DU145 prostate cancer cells
compared to unprocessed curcumin [86] As shown in Figure 5B, a significant increase in cellular uptake
of cyclodextrin–curcumin (CD–CUR) inclusion complexes (CD5, CD10, CD20, and CD30) by cancer
cells was observed compared to free curcumin. Another study found a complementary therapeutic
effect of curcumin–cyclodextrin complexes in lung cancer. Administration of these complexes to mice
with orthotopically implanted lung tumors resulted in improved bioavailability of curcumin and a
significant reduction in tumor size [87].

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Figure 5. (A) Schematic structure of cyclodextrin–curcumin (CD–CUR) inclusion and self-assembled
complexes (B) Fluorescence-activated cell sorting (FACS) analysis for cellular uptake of curcumin and
different CD–CUR (CD5, CD10, CD20, and CD30) inclusion complexes treated in DU145 prostate cancer.
* p < 0.05 represents significant difference from the curcumin uptake. Reprinted from Yallapu et al. [86]
with permission from the copyright holder Elsevier.
4. Anticancer Activity of Curcumin
One of the main causes of cancer is the loss of balance between cell proliferation and cell death [88].
When the cells skip death due to the absence of the apoptotic signals, uncontrolled cell proliferation
occurs, leading to different types of cancer [89]. The apoptotic signals are generated through two major
pathways: the intrinsic pathway and the extrinsic pathway. The intrinsic pathway works through
stimulating the mitochondrial membrane to inhibit expression of antiapoptotic proteins Bcl-2 and
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Bcl-Xl [90]. Curcumin disturbs the balance in the mitochondrial membrane potential, leading to
enhanced suppression of the Bcl-xL protein [91]. The extrinsic apoptotic pathway works through
increasing the death receptors (DRs) on cells and triggering the tumor necrosis factor (TNF)-related
apoptosis. Curcumin also contributes to this pathway by upregulating the expression of death receptors
DR 4 and DR 5 [92–94]. In vitro studies showed a remarkable ability of curcumin and its derivatives
to induce apoptosis in different cell lines by inhibiting or downregulating intracellular transcription
factors. These factors include NF-κB, activator protein 1 (AP-1), cyclooxygenase II (COX-2), nitric oxide
synthase, matrix metalloproteinase-9 (MMP-9), and STAT3 [33,73]. A recent work has found a
new anticancer mechanism for curcumin by decreasing the glucose uptake and lactate production
(Warburg effect) in cancer cells via downregulation of pyruvate kinase M2 (PKM2). The inhibition
of PKM2 was achieved by suppressing the mammalian target of rapamycin-hypoxia-inducible factor
1α (TOR-HIF1α) [95]. Several studies have investigated the ability of curcumin and its derivatives to
suppress multiple different carcinomas by interacting with different molecular targets (Figure 6).

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Figure 6. The main molecular targets of curcumin in cancer cells. ↑: Increase; ↓: Decrease; MMP: Matrix
metalloproteinase; AP-1: Activation protein-1.
4.1. In Vitro and In Vivo Studies
Curcumin has shown very promising results in suppressing cancer cell growth and proliferation
in several different types of cancer, such as prostate, colorectal, breast, pancreatic, brain, head, and neck
cancers. What comes next is a summary of the anticancer activity of curcumin and its derivatives
in different types of cancer based on the data from in vitro studies in different cancer cell lines and
animal studies.
4.1.1. Prostate Cancer
A recent estimate reported by the American Cancer Society revealed that 2.9 million men have
been diagnosed with prostate cancer (PCa) in the United States [20], making it the second leading cause
of cancer death in men [96]. Curcumin has shown a strong ability to inhibit proliferation and induce
apoptosis in prostate cancer both in vitro and in vivo [97] by interfering with a number of cellular
pathways, including mitogen-activated protein kinase (MAPK), epidermal growth factor receptor
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(EGFR), and nuclear factor κ (NFκB) [98,99]. A recent study has revealed the ability of curcumin to
activate protein kinase D1 (PKD1), leading to attenuation of the oncogenic signaling by β-catenin and
MAPK [100] and consequent inhibition of prostate cancer [100]. Moreover, PKD1 was found to be
severely downregulated following progression from androgen-dependent to androgen-independent
prostate cancer [100], and to affect the motility and invasion of prostate cancer via interaction with
E-cadherin [101]. Therefore, it has been considered as a new therapeutic target for cancer in general
and for prostate cancer in particular [102]. In addition to curcumin, some of its derivatives have also
shown anticancer activity against prostate cancer. Metallo-curcumin conjugated DNA complexes
exhibited significant toxicity to prostate cancer cells (PC3, 22Rv1, TRAMP-C1, LNCaP, and DU145) [34].
Dimethyl curcumin (ASC-J9) has also shown very good activity in enhancing androgen receptor
degradation in androgen-dependent prostate cancer [20,38].
4.1.2. Colorectal Cancer
Colorectal cancer comes third behind prostate cancer and lung cancer as the most common form
of malignant cancer [103]. Although patients diagnosed with colorectal carcinoma undertake surgical
removal of the tumor tissue along with chemotherapy, more than half of the patients suffer from
relapses [104]. Administration of curcumin was found to reduce M (1) G levels in the malignant
colorectal cells without changing COX-2 protein levels [105]. In addition, curcumin treatment was able
to downregulate miR-21 gene, which is overexpressed in colorectal cancer cells, by inhibiting AP-1
(activator protein) binding to miR-21 promoter [101]. Treating HCT 116 colorectal cancer cells with
curcumin resulted in a cell cycle arrest in the G2/M phase via miR-21 gene regulation and inhibited
the tumor tissue growth [101]. However, an in vivo study in mice with colorectal cancer demonstrated
an improved response to radiation therapy when combined with curcumin due to its ability to target
nuclear factor (NF-κB) [106]. Another study has managed to enhance curcumin inhibition activity
against colon cancer cells by combining it with ERRP, a pan-erb B inhibitor [107].
4.1.3. Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common form of cancer
worldwide, with more than 30,000 diagnosed cases every year [108]. HNSCC generally arises in the
oral cavity, paranasal cavities, larynx, and pharynx [10]. In vitro studies of curcumin in different head
and neck cancer cell lines have proven its ability to inhibit cell growth due to its effects on a number of
cellular pathways involved in cell proliferation, most notably NF-κB and STAT3, which are found to be
overexpressed in several head and neck carcinomas [109,110]. Curcumin was shown to downregulate
NF-κB and inhibit the interleukin-6 (IL-6)-mediated phosphorylation of STAT3, thus inhibiting the
proliferation of the cancer cells [110,111].
4.1.4. Breast Cancer
Breast cancer has shown an alarming record as a leading cause of death in women [112]. Despite
lumpectomy, radiation therapy, chemotherapy, and endocrine therapy, the recurrence rate of breast
cancer has been reported to be still high based on a meta-analysis of 21 retrospective studies [113].
Therefore, there is still a need for more efficient therapeutic strategies. In a study on MCF-10A human
mammary epithelial cells and MCF-7 breast cancer cells [114], a tangible drop in telomerase activity
was observed as a result of treatment with curcumin in a concentration-dependent manner which was
correlated to downregulation of hTERT by curcumin but not through the c-Myc mRNA pathway [114].
The effect of curcumin on cell-cycle regulatory proteins, matrix metalloproteinases (MMPs), and NF-κB
was evaluated in MDA-MB-231 and BT-483 breast cancer cell lines [115]. In agreement with the
previous studies on other breast cancer cell lines, this study also confirmed the ability of curcumin
to downregulate NF-κB, leading to an antiproliferative effect [115,116]. However, a decrease in
cyclic D1 in MDA-MB-231 cells and a decrease in CDK4 BT-483 were observed after treatment with
curcumin [115]. Combining arabinogalactan and curcumin enhanced apoptosis induction by increasing
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ROS levels, disturbing the mitochondrial membrane and decreasing glutathione in MDA-MB-231 cell
line [117]. Moreover, curcumin led to the inhibition of breast tumor via overexpression of the p53
gene and reduction of antigen ki-67 levels [117]. Another study on MDA-MB-231 cells has shown
that curcumin also inhibits inflammatory cytokines CXCL1/2. Inhibiting CXCL1 and 2 by curcumin
results in inhibiting the expression of a series of metastasis-promoting genes such as chemotactic
receptor CXCR4 [118,119]. Dimethyl curcumin (ASC-J9) has also been reported to be effective against
estrogen-dependent breast cancer via inhibiting several types of steroid receptors [22,120].
4.1.5. Brain Cancer and Glioblastoma
The incidence rate of central nervous system (CNS) tumors, including brain tumors, are predicted
to increase by 6% in the UK between 2014 and 2035 [121]. Glioblastoma (GBM), which is the most
common malignant brain cancer in humans, accounts for about 15% of all CNS tumors [122,123]. In the
treatment of brain tumors and GBM, surgical intervention and radiation therapy are limited due to
infiltration of cancer cells into the healthy brain, leading to damaging effects after treatment [124].
Therefore, alternative therapies using naturally derived compounds such as curcumin with less
side effects than the conventional treatments are receiving more attention. Curcumin has multiple
molecular targets (Figure 6), therefore, combating brain tumors may take different cellular pathways,
including apoptosis, autophagy, angiogenesis, invasion, andmetastasis [123]. Although penetrating the
blood–brain barrier (BBB) is considered the rate-limiting step for many anticancer agents, curcuminwas
able to cross the BBB in high levels [125]. Moreover, an in vivo study using human glioma U-87 cells
xenografted into athymic mice showed that curcumin is able to suppress glioma angiogenesis through
inhibiting MMP-9 and downregulating endothelial cell markers (CD31 and CD105 mRNA) [125].
Curcumin was also able to induce G2/M cell cycle arrest by increasing protein kinase 1 (DAPK1) in
U-251 malignant glioblastoma cells, which indicates that suppressing DAPK1 by curcumin does not
only induce cell arrest but also inhibits STAT3 and NF-κB and activates caspase-3 [126].
4.2. Clinical Studies
In addition to the studies carried out in human cell cultures or in animal models, there have been
several clinical studies carried out in human subjects to evaluate the efficacy and safety of treatment
with curcumin in different types of cancer either alone or in combination with other chemotherapy
agents. A summary of an excerpt of these clinical studies is provided in Table 3.
Table 3. Clinical studies of curcumin in the prevention/treatment of different types of cancer.
Type of
Cancer
Type of Study
No of
Patients
Dose of Curcumin Endpoints Results References
BPH a
Pilot product
evaluation study
61 1g/day for 24 weeks
Signs and symptoms,
quality of life
Reduced signs and
symptoms, improved
quality of life
[127]
Breast
Phase I clinical
trial
14
0.5–8 g/day for 7
days plus docetaxel
Maximal tolerated dose of
curcumin, toxicity, safety,
efficacy, levels of VEGF b
and tumor markers
No cancer progression,
partial response in some
patients, low frequency of
toxic effects, decreased
levels of VEGF
[128]
CML c
Randomized
controlled trial
50
5 g TID d for 6
weeks plus imatinib
(400 mg BD e)
Plasma nitric oxide levels
Reduced nitric oxide
levels
[129]
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Table 3. Cont.
Type of
Cancer
Type of Study
No of
Patients
Dose of Curcumin Endpoints Results References
Colorectal
dose-escalation
pilot study
15
40–200 mg/day for
29 days
Blood COX-2 f activity
and PGE2 g levels
Dose-dependent decrease
in PGE2 levels
[130]
Phase I
does-escalation
trial
15
0.45–3.6 g/day for
4 months
Levels of curcumin and
its metabolites in plasma
urine, and feces; levels of
PGE2 and glutathione
S-transferase activity
in blood
Dose-dependent decrease
in PGE2 levels, low
concentrations of
curcumin and its
metabolites in plasma
and urine
[131]
Phase I
does-escalation
trial
12
0.45 g, 1.8 g, 3.6 g
per day for 7 days
Concentration of
curcumin and its
metabolites in plasma
and colorectal tissue
Biologically active
concentrations of
curcumin in the colorectal
tissue
[105]
Phase I clinical
trial
126
360 mg TID for
10–30 days
Serum levels of TNF-α h,
p53 expression in
tumor tissue
Decreased serum levels of
TNF-α, increased
expression of p53 in
colorectal tissue
[132]
Phase II clinical
trial
44
2 g/day and
4 g/day for 1 month
Concentration of PGE2
and 5-HETE i within
ACF j and normal
mucosa, total ACF
number
Reduced number of ACF
with dose of 4 g
[133]
Pilot study 26
2.35 g/day for
14 days
Safety, tolerance, levels of
curcumin in colonic
mucosa
Safe and well tolerated,
Prolonged biologically
active levels of curcumin
achieved in colon tissue
[134]
HNSCC k Pilot study 21 1 g single dose
IκKβ l kinase activity,
cytokine levels in saliva
Reduced IκKβ activity in
the salivary cells
[135]
Intestinal
Adenoma
Randomized
controlled trial
44
1.5 g BID for
12 months
total number of polyps,
mean polyp size, adverse
effects
No significant clinical
response, very few
adverse effects
[136]
Pancreatic
Phase II clinical
trial
25 8 g/day for 8 weeks
Tumor response, tumor
markers, adverse effects
Poor oral bioavailability,
biological response in
only 2 patients, no
toxicities
[137]
Phase II clinical
trial
17 8 g/day for 4 weeks
Time to tumor
progression (TTP) and
toxicity profile
TTP of 1–12 months
(median 2 months), high
frequency of side effects
[138]
Phase I/II
clinical trial
21
8 g/day for 14 days
plus gemcitabine
patient compliance,
toxicity, efficacy
Safe and well tolerated,
median overall survival
time of 161 days
[139]
Phase I clinical
trial
16
200–400 mg/day for
9 months
Safety, pharmacokinetics,
NF-κB m activity,
cytokine levels, efficacy
and quality of life
Safe, highly bioavailable,
no significant changes in
NF-κB activity or
cytokine levels, improved
quality of life
[140]
Prostate
Randomized
controlled trial
85
100 mg plus 40 mg
soy isoflavones for
6 months
Serum PSA n levels
Decreased levels of PSA
in patients with an initial
PSA ≥ 10 µg/mL
[141]
Randomized
controlled trial
40
3 g/day for
3 months as a
supplement to
radiotherapy
biochemical and clinical
progression-free
survivals, alterations in
the activity of antioxidant
enzymes
Considerable antioxidant
effect, decreased levels
of PSA
[142]
Solid tumors
Randomized
controlled trial
80
180 mg/day for
8 weeks
Changes in quality of life,
serum levels of
inflammatory mediators
Improved quality of life,
reduced levels of
inflammatory mediators
[143]
a BPH: benign prostatic hypertrophy; b VEGF: vascular endothelial growth factor; c CML: chronic myeloid leukemia;
d TID: three times daily; e BD: Twice daily; f COX-2: cyclooxygenase-2; g PGE2: Prostaglandin E2; h TNF-α: tumor
necrosis factor α; i 5-HETE: 5-hydroxyeicosatetraenoic acid; j ACF: aberrant crypt foci; k HNSCC: Head and neck
squamous cell carcinoma; l IκKβ: IκB kinase β; m NF-κB: Nuclear factor κB; n PSA: prostate-specific antigen.
4.2.1. Colorectal Cancer
The pharmacology of curcumin in humans was studied in a dose-escalation study by
Sharma et al. [131] on fifteen patients with histologically proven advanced adenocarcinoma of the
colon or rectum refractory to standard chemotherapies. The patients received doses of curcumin
Int. J. Mol. Sci. 2019, 20, 1033 15 of 26
between 0.45 and 3.6 g per day orally for up to four months. Subsequently, levels of curcumin and its
metabolites in plasma, urine, and feces were measured. In addition, glutathione S-transferase (GST)
activity, levels of oxidative DNA adduct (M1G), and the extent of ex vivo induction of prostaglandin E2
(PGE2) in patient blood leukocytes were measured as biomarkers of curcumin activity. Intact curcumin
and its glucuronide and sulfate conjugates were detected in plasma at a concentration of 10 nmol/L
and also in urine. No dose-limiting toxicity was observed. No effect on basal PGE2 levels in leukocytes
was observed after administration of curcumin at any of the doses, nor were there any changes
in the lipopolysaccharide (LPS)-induced production of PGE2 at doses between 0.45 and 1.8 g per
day. However, administration of 3.6 g curcumin per day led to 62% and 57% reductions in the
inducible PGE2 levels in patient blood samples 1 h after administration on days 1 and 29, respectively,
compared to the baseline levels. Total GST activity and M1G levels in leukocytes showed considerable
differences between patients, but no treatment-related effects were observed. Based on these results,
they suggested a daily oral dose of 3.6 g of curcumin for a Phase II trial in cancers in sites outside the
gastrointestinal tract which require systemic effects [131].
The pharmacological activity of curcumin in the colorectumwas also studied by Garcea et al. [105]
as measured by the levels of M1G and COX-2 in 12 patients with colorectal carcinoma following oral
administration of curcumin at doses of 450 mg, 1800 mg, or 3600 mg per day. Blood samples and biopsy
samples of the normal and malignant colorectal tissue were taken from the patients at designated
time points and analyzed for the levels of curcumin, curcumin metabolites (curcumin sulfate and
curcumin glucuronide), M1G, and COX-2. Higher concentrations of curcumin were observed in normal
compared to malignant colorectal tissues of patients receiving 3.6 g/day of curcumin, with trace levels
of curcumin in the peripheral blood circulation. Curcumin metabolites were also detected in the
colorectum of these patients. On the other hand, baseline M1G levels were 2.5-fold higher in malignant
tissue as compared with normal tissue in the same group of patients, which were reduced significantly
after the administration of curcumin. Nevertheless, the levels of COX-2 in malignant colorectal
tissue were not reduced by curcumin. Based on these findings, they suggested that a daily dose of
3.6 g of curcumin can reach pharmacologically active concentrations in the colorectum with minimal
distribution outside the gastrointestinal system [105].
The mechanism of anticancer activity of curcumin in colorectal cancer was investigated by a
number of researchers. In 2001, Plummer et al. [130] conducted a dose-escalation pilot study of
the effects of Curcuma extract (containing curcumin and desmethoxycurcumin) on the inhibition of
COX-2 activity and consequently the levels of PGE2 in 15 patients with advanced colorectal cancer.
The patients were divided into five groups receiving doses between 40 and 200 mg of curcuminoids
once per day via the oral route for a minimum of 29 days. Comparison of the PGE2 levels in blood
samples from patients showed a significant difference between patients in different groups and
decreased levels of PGE2 with an increased dose of curcumin, which clearly indicates dose-dependent
inhibition of COX-2 by curcumin [130].
This was further investigated by Carroll et al. [133] who carried out a nonrandomized, open-label
clinical trial to assess the effects of oral curcumin in prevention of colorectal cancer. In the study,
44 smokers with eight or more aberrant crypt foci (ACF) on screening colonoscopy were included and
were divided into two groups receiving either 2 g or 4 g of curcumin per day via the oral route for
30 days. The levels of PGE2 and 5-hydroxyeicosatetraenoic acid (5-HETE) within ACF were assessed,
as well as the reduction in the number and/or proliferation of ACF (measured by rectal endoscopy and
Ki-67 immunohistochemistry assay, respectively). ACF reduction was used as a measure of the cancer
preventive efficacy of curcumin, assuming that reducing the concentrations of PGE2 and 5-HETE in
the colorectal mucosa would result in reduced epithelial crypt proliferation and ACF formation.
No reduction in the levels of PGE2 or 5-HETE within ACF or normal mucosa was observed with
any doses of curcumin, nor was there any reduction in the levels of Ki-67 in normal mucosa. By the
same way, there were no changes in the number of ACF in the group treated with 2 g of curcumin.
However, a significant reduction in the number of ACF was observed in the group treated with 4 g of
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curcumin, which was associated with a significant increase in the plasma levels of curcumin conjugates,
indicating the effect of systematically delivered curcumin conjugates on the reduction of ACF number,
rather than locally delivered curcumin [133].
He et al. [132] investigated the effects of curcumin on the expression of p53 in the colorectum tissue
and the serum levels of TNF-α in patients with colorectal cancer. A total of 126 patients diagnosed
with colorectal cancer were randomly divided into two groups receiving either curcumin (360 mg three
times per day per oral route) or placebo during the period ahead of surgery. Colorectal biopsy samples
and blood samples were obtained from the patients before and after treatment and were analyzed for
p53 expression and serum TNF-α levels respectively. A significant reduction in the serum levels of
TNF-αwas observed in the patients treated with curcumin, whereas no such effect was observed in
the placebo group. In the same way, the number of apoptotic cells was increased after treatment with
curcumin compared to baseline values, whereas no significant change was observed in the placebo
group. Moreover, treatment with curcumin increased the expression of p53 and Bax and inhibited
expression of Bcl-2 in the colorectal tissue [132].
More recently, the safety and efficacy of curcumin in familial adenomatous polyposis was
evaluated in a double-blinded randomized trial by Cruz-Correa et al. [136]. In this study, 44 patients
with familial adenomatous polyposis with at least five intestinal adenomatous polyps who had not
undergone colectomy were included in this trial and were randomly allocated to two groups receiving
either pure curcumin (3 g per day orally) or placebo for 12 months. The main outcome measures were
the number and size of lower gastrointestinal tract polyps, which were assessed every four months for
one year. At the end of the study, no significant difference was found in the mean number or mean
size of polyps between the curcumin group and the placebo group. The adverse effects were very few,
and not significantly different from the placebo group. These results show the low efficacy but high
safety of oral curcumin at the administered dose in patients with familial adenomatous polyposis [136].
4.2.2. Pancreatic Cancer
The efficacy of curcumin in the treatment of pancreatic cancer was investigated in a
nonrandomized, open-label, phase II clinical trial conducted by Dhillon et al. [137]. In this study,
25 patients with histologically confirmed pancreatic adenocarcinoma were treated with a combination
of curcuminoids (curcumin, desmethoxycurcumin, and bisdesmethoxycurcumin), at a dose of 8 g per
day for eight weeks. The patients did not receive any chemotherapy or radiotherapy from four weeks
before commencing the trial and also during the trial. Tumor response (as per the classic Response
Evaluation Criteria in Solid Tumors criteria), tumor markers, and serum cytokine levels were assessed
after 8 weeks. In addition, the effect of orally administered curcumin on constitutive and tumor
necrosis factor-α–induced binding expression of NF-κB, COX-2, and phosphorylated signal transducer
and activator of transcription 3 (pSTAT3) in peripheral blood mononuclear cells pretherapy and on
day 8 were determined, as well as curcumin pharmacokinetics.
Low steady-state levels of curcumin glucuronide and curcumin sulfate indicated poor oral
bioavailability. As a result, only two patients showed a clinical biological response to curcumin therapy,
and one other patient showed a brief tumor regression accompanied by a considerable increase in
serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). On the other hand, curcumin
down-regulated the expression of NF-κB, COX-2, and pSTAT3 in peripheral blood mononuclear cells
obtained from patients. No treatment-related toxic effects were reported in any patients [137].
In a more recent study by Epelbaum et al. [138], patients with either advanced local or metastatic
pancreatic cancer were treated with a combination of curcumin (8 g/day per oral) and gemcitabine
(1000 mg/m2 IV once per week) for three out of four weeks of each chemotherapy cycle. The primary
outcome was time to tumor progression and the main secondary outcome was toxicity profile. In the
study, eight out of seventeen patients were noncompliant with curcumin due to abdominal pain,
five of which discontinued treatment before two weeks and three received adjusted doses of curcumin
for the rest of the study (4 g/day). One patient died during the first cycle due to cardiac problems
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not associated with curcumin. One patient developed grade II neutropenia and one patient grade I
thrombocytopenia. The time to tumor progression was between one and twelve months (median two
months), and the overall survival time was between one and 24 months (median 6). Based on these
results, they concluded that the combination therapy with curcumin and gemcitabine in pancreatic
cancer is feasible; however, the dose of curcumin should be less than 8 g/day [138].
4.2.3. Prostate Cancer
In a double-blinded, randomized, placebo-controlled trial by Hejazi et al. [142], the effect of
curcumin on the oxidative status of patients with prostate cancer during radiotherapy was evaluated.
In this study, 40 patients were included in the trial and were randomly assigned to receive either
curcuminoids (curcumin, desmethoxycurcumin, and bisdesmethoxycurcumin, 3 g per day per oral
route) or placebo prior to and during external-beam radiation therapy. The outcome measures for
oxidative status were the plasma total antioxidant capacity (TAC), superoxide dismutase (SOD) activity,
catalase activity, and glutathione peroxidase activity, three months after radiotherapy. In addition,
the level of prostate specific antigen (PSA) was used as a measure of successful treatment.
A significant increase in TAC and a significant decrease in SOD activity was observed after
radiotherapy compared to the baseline (pretreatment) values, suggesting an antioxidant effect of
curcumin, whereas no significant changes were observed in catalase activity and glutathione peroxidase
activity. The levels of PSA were significantly reduced compared to baseline levels in both groups,
indicating successful treatment; nevertheless, there was no significant difference between the two
groups, indicating that curcumin did not affect the efficacy of the radiotherapy [142].
The effect of a combination of curcumin and soy isoflavones on the expression of PSA in men
with elevated levels of PSA (but neither prostate cancer nor prostatic intraepithelial neoplasia) was
investigated in a randomized placebo-controlled double-blind study by Ide et al. [141]. A total of
85 patients were included in this study and were randomly assigned to receive either a supplement
containing a combination of isoflavones and curcumin or placebo. Systematic prostate biopsy was
performed on the patients before and sixmonths after treatment, and the levels of PSAwere determined.
The curcumin/isoflavone treatment considerably decreased the levels of PSA in the patients with an
initial PSA ≥ 10 µg/mL as compared to the placebo group who did not show such change, which
they attributed to the synergistic antiandrogen effect of curcumin and isoflavones [141]. However,
since there was no comparison between the effects of treatment with isoflavones alone and curcumin
alone compared to combination therapy on the levels of PSA, it is hard to accept the authors’ claim
that the combination therapy has advantages over monotherapy as no such evidence is provided.
4.2.4. Breast Cancer
Bayet-Robert et al. [128] evaluated the feasibility and tolerability of a combination of curcumin
and docetaxel in 14 patients with metastatic or locoregionally recurrent advanced breast cancer
in an open-label phase I dose escalation clinical trial. The patients received an I.V. infusion of
Docetaxel (100 mg/m2) every three weeks for six chemotherapy cycles, and oral curcumin (starting
from 500 mg/day and increased until a dose-limiting toxicity would occur) for seven consecutive
days in each cycle (from five days before to two days after administration of docetaxel). The primary
endpoint was the maximal tolerated dose of curcumin when administered in combination with a
standard dose of docetaxel in the patients. Secondary outcomes were toxicity, safety, and clinical
response to the combination therapy, as well as levels of CEA tumor marker and vascular endothelial
growth factor (VEGF) as a positive endogenous modulator of angiogenesis.
The maximal tolerated dose of curcumin was found to be 8 g/day as in higher doses, dose-limiting
toxicities (neutropenia, anemia, and severe diarrhea) were observed, leading to the discontinuation
of the trial in two patients. Other toxicities (oral cavity mucositis, hand-foot syndrome, nail changes,
dermal changes, conjunctivitis, and fatigue) were either not persistent or were treated easily so did
not affect the continuation of the trial. However, due to noncompliance of a number of patients with
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the doses higher than 6 g/day, in the end, this dose was recommended as the maximal tolerated dose
to be considered for phase II clinical trials. In terms of clinical and biological response (decrease in
CEA tumor marker across the treatment and regression of nonmeasurable lesions), some degree of
improvement was observed in most patients, with five patients showing a partial response to treatment
and three patients having stable disease at least six weeks after the last cycle of treatment. No disease
progression was observed in any of the patients. Moreover, curcumin/docetaxel combination
significantly decreased the levels of VEGF after three cycles of treatment [128].
4.2.5. Head and Neck Cancer
Kim et al. [135] performed a pilot study in patients with head and neck squamous cell carcinoma
(HNSCC) to determine the effect of curcumin on inhibiting IκB kinaseβ (IκKβ) activity and suppressing
the proinflammatory cytokines. The patients were asked to chew curcumin tablets (2 mg), their saliva
samples were collected before and after chewing the tablets, and the IκKβ activity was measured,
as well as the levels of salivary cytokines interleukin (IL)-6 and IL-8. Curcumin resulted in a reduction
in IκKβ activity in the salivary cells of HNSCC patients. There was a brief reduction in IL-8 expression
in eight of 21 post-curcumin samples; however, this reduction was not statistically significant. On the
other hand, there was a marked decrease in the expression of other cytokines, including IL-10, IFN-γ,
IL-12p70, and IL-2 clustered together, and also granulocyte macrophage colony stimulating factor
(GMCSF) and TNF-α clustered together. These results show the inhibitory effect of curcumin on IκKβ
activity in the salivary cells of patients with HNSCC; therefore, they suggested considering IκKβ as a
biomarker for detecting the effect of curcumin in head and neck cancer [135].
5. Conclusions and Future Perspectives
Curcumin, the active ingredient of the Curcuma longa extract, has been studiedwidely over the past
few decades for its anti-inflammatory, antioxidant, anticancer, and antiandrogenic effects. Curcumin
has shown considerable anticancer effects against several different types of cancer, including prostate
cancer, breast cancer, colorectal cancer, pancreatic cancer, and head and neck cancer both in vitro and
in vivo. Furthermore, its efficacy and safety in cancer patients either alone or in combination with
other anticancer agents has been proven in several clinical studies with human subjects. Curcumin is
believed to exert its anticancer activity via multiple mechanisms, interfering with different cellular
pathways and inducing/inhibiting the production of various types of cytokines, enzymes or growth
factors such as MAPK, EGF, NFκB, PKD1, COX-2, STAT3, TNF-α, and IκKβ. However, the anticancer
application of curcumin has been limited mainly due to its low water solubility, which results in low
cellular uptake and poor oral bioavailability, as well as low chemical stability. In order to overcome
these limitations, different approaches have been made, such as structural modification and the use of
drug delivery systems. The key pharmacophores contributing to the biological activity of curcumin are
known to be the hydrogen donor group, the β-diketone moiety, the phenyl rings, and the substituent
groups on them. Chemical modification of these moieties has led to curcumin derivatives with higher
efficacy and/or enhanced water solubility or stability. In addition, various types of delivery systems
have been developed for curcumin delivery to cancer cells or animal xenografts using a variety of
natural or synthetic polymers, lipids, or proteins, some of which have improved the stability and/or
cellular uptake of curcumin, thus giving rise to a stronger anticancer response.
In spite of the tremendous effort to improve the physicochemical and biological properties
of curcumin, there are still several issues to be addressed in regard to its bioavailability, potency,
and specificity for the target tissue. The medicinal chemistry approaches to improving the
pharmacological properties of curcumin have not managed to increase its potency significantly, and the
curcumin derivatives are not more potent than curcumin itself. Due to the low potency of curcumin
and its derivatives, higher doses are required to see a therapeutic response, which increases the adverse
effects and reduces the patient compliance. Another drawback of the structural modification is that it is
difficult to achieve a balance between efficacy and solubility, and in most cases, one has been sacrificed
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in favor of the other. Most of the structural modifications that improve curcumin efficacy make the
molecule more hydrophobic and reduce its solubility. Therefore, more work has to be done in this
regard to overcome this problem. Although various types of drug delivery systems have been used
to enhance the cellular uptake and efficacy of curcumin, most of these formulations have remained
at the proof of concept level and have not been evaluated in clinical trials. There is a lack of clinical
studies to evaluate the safety and efficacy of these curcumin delivery systems in humans before they
can find their way to the pharmaceutical market. Moreover, most of the currently developed drug
delivery systems for curcumin lack specificity for the target tissue. Hence, there is still much room
for improvement in the curcumin delivery systems in terms of selectivity for specific tumor tissues.
Tissue-specific curcumin delivery enhances the local drug concentrations in the site of action and
therefore results in higher efficacy (with lower doses of curcumin) and less adverse effects.
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